An International Phase 3, Randomized, Double-Blind, Placebo- and Active (Tolterodine)-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Vibegron in Patients With Symptoms of Overactive Bladder
Phase of Trial: Phase III
Latest Information Update: 16 Apr 2018
At a glance
- Drugs Vibegron (Primary) ; Tolterodine
- Indications Overactive bladder
- Focus Registrational; Therapeutic Use
- Acronyms EMPOWUR
- Sponsors Urovant Sciences
- 28 Mar 2018 Status changed from planning to recruiting, according to an Urovant Sciences media release.
- 18 Sep 2017 According to an Urovant Sciences media release, the company plans to initiate this confirmatory phase III trial by early 2018.
- 19 Jun 2017 New trial record